Novo Nordisk A/S NONOF

Company Overview

Novo Nordisk A/S is a global healthcare company focused on the discovery, development, manufacturing, and commercialization of pharmaceutical products. The company operates primarily within the pharmaceuticals and biotechnology industries, with a longstanding specialization in treatments for diabetes, obesity, and rare chronic diseases. Its core revenue is driven by injectable and oral therapies addressing metabolic and endocrine disorders, particularly GLP-1–based therapies, insulin products, and biopharmaceutical treatments for hemophilia and growth disorders.

Founded in 1923 in Denmark, Novo Nordisk emerged from early insulin production and evolved into one of the world’s largest diabetes-focused drug manufacturers. Over the decades, the company expanded its therapeutic focus to obesity and rare diseases, while maintaining a vertically integrated business model encompassing research, development, manufacturing, and global distribution. Novo Nordisk is publicly listed in Denmark and trades in the U.S. through American Depositary Receipts, including the OTC ticker NONOF.